To report results of hyperfractionated radiotherapy for T2N0 glottic carcinoma at a single institution after extended follow-up.
Methods
Between 1980 and 1988 at Varese University Hospital, 60 consecutive patients with T2N0 glottic carcinoma received exclusive radiotherapy consisting of 1.5 Gy/fraction twice a day. Treatment gaps during the radiotherapy course were allowed according to individual tolerance. This policy resulted in a wide range of elapsed treatment time: median, 5.7 weeks; range, 3.7-8.9. Median follow-up is 9.8 years.
Results
As a result of dose/time distribution, 16, 20 and 24 patients received an average weekly dose rate of <10 Gy/week, equal to 10 Gy/week or >10 Gy/week, respectively. Mean total dose for each group was 62.8 Gy, 63.7 Gy and 63.8 Gy, respectively. Five-year local-regional control was 69 ± 6% (95% Cl); ultimate local-regional control, including salvage surgery, was 78 ± 5%. All failures were at the primary site, and no patient developed neck recurrence as first site of failure. The actuarial incidence of grade 2-3 late reactions at 5 years was 42 ± 6%. Most late toxicity events were grade 2: only 2 patients developed grade 3 reactions and none grade 4. None of the several clinical and treatment-related variables showed any statistically significant impact on local-regional control or late toxicity at univariate and multivariate analysis. In particular, 3-year local-regional control rates were 73 ± 11%, 84 ± 8% and 69 ± 10% for an average weekly dose rate of <10 Gy/week, equal to 10 Gy/week and >10 Gy/week, respectively (not significantly different).
Conclusions
At a very long follow-up, the hyperfractionated regimen tested in the study was shown to be effective and devoid of major complications, provided individual patient acute tolerance is carefully taken into account. Also, time factor did not affect outcome in this series.
HarwoodA.R., BealeF.A., CummingsB.J., KeaneT.J., RiderW.D.: T2 glottic cancer: an analysis of dose-time-volume factors. Int J Radiat Oncol Biol Phys, 7: 1501–1505, 1981.
2.
KarimA.B., KralendonkJ.H., YapL.Y., NjoK.H., TierieA.H., TiwariR.M., SnowG.B., GerritsenG.J., HasmanA.: Heterogeneity of stage II glottic carcinoma and its therapeutic implications. Int J Radiat Oncol Biol Phys, 13: 313–317, 1987.
3.
LeQ.T., FuK.K., KrollS., RyuJ.K., QuiveyJ.M., MeylerT.S., KriegR.M., PhillipsT.L.: Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys, 39: 115–126, 1997.
4.
MediniE., MediniI., LeeC.K., GapanyM., LevittS.H.: Curative radiotherapy for stage II-III squamous cell carcinoma of the glottic larynx. Am J Clin Oncol, 21: 302–305, 1998.
5.
MendenhallW.M., ParsonsJ.T., MillionR.R., FletcherG.H.: T1-T2 squamous cell carcinoma of the glottic larynx treated with radiation therapy: relationships of dose-fractionation factors to local control and complications. Int J Radiat Oncol Biol Phys, 15: 1267–1273, 1988.
6.
NishimuraY., NagataY., OkajimaK., MitsumoriM., HiraokaM., MasunagaS., OnoK., ShojiK., KojimaH.: Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control. Radiother Oncol, 40: 225–232, 1996.
7.
Van den BogaertW., OstynF., van der SchuerenE.: The significance of extension and impaired mobility in cancer of the vocal cord. Int J Radiat Oncol Biol Phys, 9: 181–184, 1983.
8.
WangC.C., EfirdJ.T.: Does prolonged treatment course adversely affect local control of carcinoma of the larynx?Int J Radiat Oncol Biol Phys, 29: 657–660, 1994.
9.
JohansenL.V., GrauC., OvergaardJ.: Glottic carcinoma: patterns of failure and salvage treatment after curative radiotherapy in 861 consecutive patients. Radiother Oncol, 63: 257–267, 2002.
10.
JorgensenK., GodballeC., HansenO., BastholtL.: Cancer of the larynx. Treatment results after primary radiotherapy with salvage surgery in a series of 1005 patients. Acta Oncol, 41: 69–76, 2002.
11.
Howell-BurkeD., PetersL.J., GoepfertH., OswaldM.J.: T2 glottic cancer. Recurrence, salvage, and survival after definitive radiotherapy. Arch Otholaryngol Head Neck Surg, 116: 830–835, 1990.
12.
SakataK., AokiY., KarasawaK., HasezawaK., MutaN., NakagawaK., TeraharaA., OnogiY., SasakiY., AkanumaA.: Radiation therapy in early glottic carcinoma: uni- and multivariate analysis of prognostic factors affecting local control. Int J Radiat Oncol Biol Phys, 30: 1059–1064, 1994.
13.
MendenhallW.M., ParsonsJ.T., StringerS.P., CassisiN.J., MillionR.R.: T1-T2 vocal cord carcinoma: a basis for comparing the results of radiotherapy and surgery. Head Neck Surg, 10: 373–377, 1988.
14.
OguraJ.H., SessionsD.G., SpectorG.J.: Analysis of surgical therapy for epidermoid carcinoma of the laryngeal glottis. Laryngoscope, 85: 1522–1530, 1975.
15.
BurkeL.S., GrevenK.M., McGuirtW.T., CaseD., HoenH.M., RabenM.: Definitive radiotherapy for early glottic carcinoma: prognostic factors and implications for treatment. Int J Radiat Oncol Biol Phys, 38: 1001–1006, 1997.
16.
FeinD.A., LeeW.R., HanlonA.L., RidgeJ.A., CurranW.J., CoiaL.R.: Do overall treatment time, field size, and treatment energy influence local control of T1-T2 squamous cell carcinomas of the glottic larynx?Int J Radiat Oncol Biol Phys, 34: 823–831, 1996.
17.
SakataK., OouchiA., NagakuraH., AkibaH., TamakawaM., KoitoK., HareyamaM., AsakuraK., SatohM., OhtaniS.: Accelerated radiotherapy for T1,2 glottic carcinoma: analysis of the results with KI-67 Index. Int J Radiat Oncol Biol Phys, 47: 81–88, 2000.
18.
UICC (International Union Against Cancer):TNM classification of malignant tumors (3rd edition): Springer-Verlag, Berlin, 1978.
19.
UICC (International Union Against Cancer):TNM classification of malignant tumors (5th edition): Wiley-Liss, New York, 1997.
20.
ShukovskyL.J., FletcherG.H., MontagueE.D., WithersH.R.: Experience with twice a day fractionation in clinical radiotherapy. Am J Roentgenol, 126: 155–162, 1976.
21.
SvobodaV.H.: Radiotherapy by several sessions a day. Br J Radiol, 48: 131–233, 1975.
22.
Van den BogaertW., van der SchuerenE., HoriotJ.C., ChaplainG., ArcangeliG., GonzalezD., SvobodaV.: The feasibility of high-dose multiple daily fractionation and its combination with anoxic cell sensitiziers in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys, 8: 1649–1655, 1982.
23.
ViscontiM., BertoniF., BianchiN., BignardiM., CassaniE., ConteL.: Irradiazione del collo con tecnica pendolare tangenziale. Radiol Med, 75: 210–214, 1988.
24.
BratengeierK., PfreundnerL., FlentjeM.: Radiation techniques for head and neck tumors. Radiother Oncol, 56: 209–220, 2000.
25.
ICRU (International Commission on Radiation Units and Measurements):Prescribing, recording and reporting photon beam therapy, ICRU report 50.International Commission on Radiation Units and Measurements, Bethesda, 1993.
26.
CoxJ.D., StettzJ.A., PajakT.F.: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC):Int J Radiat Oncol Biol Phys, 31: 1341–1346, 1995.
27.
KaplanE.R., MeierP.: Non-parametric estimation and incomplete observations. J Am Stat Ass, 53: 457–481, 1958.
28.
PetoR., PikeM.C., ArmitageP., BreslowN.E., CoxD.R., HowardS.V., MantelN., McPhersonK., PetoJ., SmithP.G.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer, 35: 1–39, 1977.
29.
CoxD.R.: Regression models and life tables. J R Stat Soc, 34: 187–220, 1972.
30.
FeinD.A., LeeW.R., HanlonA.L., RidgeJ.A., LaugerC.J., CurranW.J., CoiaL.R.: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol, 13: 2077–2083, 1995.
31.
FranchinG., MinatelE., GobittiC., SalaminiR., SartorG., CarusoG., GradoG., PolitiD., GiganteM., ToffoliG., TrovòG., BarzanL.: Radiation treatment of glottic squamous cell carcinoma, stage I and II: analysis of factors affecting prognosis. Int J Radiat Oncol Biol Phys, 40: 541–548, 1998.
32.
LeeJ.H., MachtayM., McKennaM.G., WeinsteinG.S., MarkiewiczD.A., KrischR.E., KligermanM.M.: Radiotherapy with 6-megavolt photons for early glottic carcinoma: potential impact of extension to the posterior vocal cord. Am J Otolaryngol, 22: 43–54, 2001.
33.
MarshakG., BrennerB., ShveroJ., ShapiraJ., OphirD., HochmanI., MarshakG., SulkerA., RabowskyE.: Prognostic factors for local control of early glottic cancer: the Rabin Medical Center retrospective study on 207 patients. Int J Radiat Oncol Biol Phys, 43: 1009–1013, 1999.
34.
SlevinN.J., VasanthanS., DougalM.: Relative clinical influence of tumor dose versus dose per fraction on the occurrence of late normal tissue morbidity following larynx radiotherapy. Int J Radiat Oncol Biol Phys, 25: 23–28, 1992.
35.
SpectorJ.G., SessionsD.G., ChaoK.S.C., HansonJ.M., SimpsonJ.R., PerezC.A.: Management of stage II (T2N0M0) glottic carcinoma by radiotherapy and conservation surgery. Head Neck, 21: 116–123, 1999.
36.
MendenhallW.M., AmdurJ.R., MorrisC.G., HinermanR.W.: T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol, 19: 4029–4036, 2001.
37.
RicciardelliE.J., WeymullerE.A.Jr., KohW.J., Austin-SeymourA., De SautelM.G., LaramoreG.E.: Effect of radiation fraction size on local control rates for early glottic carcinoma. A model analysis for in vivo tumor growth and radio-response parameters. Arch Otholaryngol Head Neck Surg, 120: 737–742, 1994.
38.
SchwaiboldF., ScariatoA., NunnoM., WallnerPe, LustigR.A., RoubyE., GorsheinD., WengerJ.: The effect of fraction size on control of early glottic cancer. Int J Radiat Oncol Biol Phys, 14: 451–454, 1988.
39.
HendryJ.H., RobertsS.A., SlevinN.J., KeaneT.J., BartonM.B., Agren-CronqvistA.: Influence of radiotherapy treatment time on control of laryngeal cancer: comparisons between centers in Manchester, UK and Toronto, Canada. Radiother Oncol, 31: 14–22, 1994.
40.
OvergaardJ., Hjelm-HansenM., JohansenL.V., AndersenA.P.: Comparison of conventional and split-course as primary treatment in carcinoma of the larynx. Acta Oncol, 27: 147–161, 1988.
41.
Van PuttenW.L.J., van der SaugenM.J.C., HoekstraC.J.M., LevendagP.C.: Dose, fractionation and overall treatment time in radiation therapy. The effects on local control for cancer of the larynx. Radiother Oncol, 30: 97–108, 1994
42.
FowlerJ.F.: Fractionation in glottic carcinoma. Int J Radiat Oncol Biol Phys, 39: 1–2, 1997.
43.
StuschkeM., ThamesH.D.: Fractionation sensitivities and dose-control relationships of head and neck carcinomas: analysis of randomized hyperfractionation trials. Radiother Oncol, 51: 113–121, 1999.
44.
KaandersJ.H., van DaalW.A., HoogenraadW.J., van der KogelA.J.: Accelerated fractionation radiotherapy for laryngeal cancer, acute and late toxicity. Int J Radiat Oncol Biol Phys, 24: 497–503, 1992.
45.
FeinD.A., MendenhallW.M., ParsonsJ.T., MillionR.R.: T1-T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control. Int J Radiat Oncol Biol Phys, 25: 605–611, 1993.
46.
GardenA.S., ForsterK., WongP.F., MorrisonW.H., Schechter NR AngK.K.: Results of radiotherapy for T2N0 glottic carcinoma: does the “2” stand for twice-daily treatment?Int J Radiat Oncol Biol Phys, 55: 322–328, 2003.
47.
HaugenH., JohanssonK.A., MerckeC.: Hyperfractionated-accelerated or conventionally fractionated radiotherapy for early glottic cancer. Int J Radiat Oncol Biol Phys, 52: 109–1192002.
48.
BernierJ., BentzenS.M.: Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer, 39: 560–5712003.
49.
FuK.K., WoodhouseR.J., QuiveyJ.M., PhillipsT.L., DedoH.H.: The significance of laryngeal edema following radiotherapy of carcinoma of the vocal cord. Cancer, 49: 655–658, 1982.
50.
LoefflerR.K.: Influence of fractionation on acute and late reactions in vocal cord carcinoma. Am J Roentgenol Radium Ther Nucl Med, 121: 748–753, 1974.
51.
DenhamJ.W., PetersL.J., JohansenJ., PoulsenM., LambD.S., HindleyA., O'BrienP.C., SpryN.A., PennimentM., KrawitzH.: Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?Radiother Oncol, 52: 157–164, 1999.
52.
PetersL.J., AngK.K., ThamesH.D.: Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol, 27: 185–194, 1988.
53.
BartonM.B., KeaneT.J., GadallaT., MakiE.: The effect of treatment time and treatment interruption on tumor control following radical radiotherapy of laryngeal cancer. Radiother Oncol, 23: 137–143, 1992.
54.
DuncanW., MacDougallR.H., KerrG.R., DowningD.: Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer. Radiother Oncol, 41: 203–207, 1996.
55.
RobertsonC., RobertsonA.G., HendryJ.H., RobertsS.A., SlevinN.J., DuncanW.B., MacDougallR.H., KerrG.R., O'SullivanB., KeaneT.J.: Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys, 40: 319–329, 1998.
56.
RobertsonA.G., RobertsonC., PeroneC., ClarkeK., DewaarJ., EliaM.H., HurmannD., MacDougallR.H., YosefH.M.A.: Effect of gap length and position on results of treatment of cancer of the larynx in Scotland by radiotherapy: a linear quadratic analysis. Radiother Oncol, 48: 165–173, 1998.
57.
SkladowskiK., LawM.G., MaciejewskiB., SteelG.G.: Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. Radiother Oncol, 30: 109–120, 1994.
58.
SlevinN.J., HendryJ.H., RobertsS.A., Agren-CronqvistA.: The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapy. Radiother Oncol, 24: 215–220, 1992.
59.
Van den BogaertW., van der LeestA., RijndersA., DelaereP., ThamesH., van der SchuerenE.: Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer?Radiother Oncol, 36: 177–182, 1995.
60.
TaylorJ.M., WithersH.R.: Influences of selection bias on dose-time analysis: a theoretical investigation. Radiother Oncol, 40: 259–270, 1996.
61.
GearaF.B., PetersL.J., AngK.K., GardenA.S., TuckeS.L., LevyL.B., BrownB.W.: Comparison between normal tissue reactions and local tumor control in head and neck cancer patients treated by definitive radiotherapy. Int J Radiat Oncol Biol Phys, 35: 455–462, 1996.
62.
RudatV., DietzA., NollertJ., ConradtC., WeberK.J., FlentjeM., WannenmacherM.: Acute and late toxicity, tumor control and intrinsic radiosensitivity of primary fibroblasts in vitro of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol, 53: 233–245, 1999.
63.
WangC.C., EfirdJ.T., NakfoorB., MartinsP.: Local control of T3 carcinomas after accelerated fractionation: a look at the “gap”. Int J Radiat Oncol Biol Phys, 35: 439–441, 1996.
